Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 43kWORD 10k
27 October 2021
Priority question for written answer  P-004862/2021
to the Commission
Rule 138
Francesca Donato (NI)
 Answer in writing 
 Subject: Post-COVID vaccine deaths

Three young people recently lost their lives after receiving their second dose of the COVID vaccine(1). These cases are the latest to be added to the growing list of sudden deaths to occur during the vaccine rollout.

The recent autopsy report for Camilla Canepa(2), who also died following vaccination, stated that the cause of death could be ‘reasonably attributed to an adverse effect from administration of the COVID vaccine’.

A German study(3) examining the autopsies of people who died shortly after vaccination suggests that 50% of these deaths were caused by the vaccine, which is also believed to be behind an unprecedented accumulation of lymphocytes found in the hearts, kidneys, livers and spleens of the deceased.

In the light of the above:

1. Does the Commission intend to reanalyse the costs and benefits of vaccinating young people, given the absolute risk of serious – or even fatal – adverse effects?

2. Will it withdraw the emergency use authorisation for the vaccines – at least for the under-50s, for whom the serious risks associated with vaccination appear to outweigh the limited benefits?

Original language of question: IT
Last updated: 3 November 2021Legal notice - Privacy policy